PainReform Ltd. (NASDAQ:PRFX) Short Interest Down 54.2% in January

PainReform Ltd. (NASDAQ:PRFX) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 25,600 shares, a drop of 54.2% from the December 31st total of 55,900 shares. Based on an average daily volume of 3,390,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 3.0% of the company’s shares are sold short.

PainReform Price Performance

NASDAQ:PRFX traded down $0.08 during mid-day trading on Thursday, hitting $3.27. 71,809 shares of the company’s stock were exchanged, compared to its average volume of 1,127,865. The business has a fifty day moving average price of $3.42 and a 200 day moving average price of $2.61. The company has a market cap of $473,425.00, a PE ratio of -0.02 and a beta of 0.64. PainReform has a one year low of $1.73 and a one year high of $61.20.

Wall Street Analyst Weigh In

Separately, Maxim Group restated a “hold” rating on shares of PainReform in a research report on Thursday, October 24th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PainReform stock. Apollon Wealth Management LLC acquired a new stake in shares of PainReform Ltd. (NASDAQ:PRFX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 12,917 shares of the company’s stock, valued at approximately $43,000. Apollon Wealth Management LLC owned about 9.23% of PainReform as of its most recent SEC filing. Institutional investors own 37.28% of the company’s stock.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.